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Calcineurin (CN) is a highly conserved Ca2+–calmodulin (CaM)-
dependent phosphatase that senses Ca2+ concentrations and trans-
duces that information into cellular responses. Ca2+ homeostasis
is disrupted by α-synuclein (α-syn), a small lipid binding protein
whose misfolding and accumulation is a pathological hallmark of
several neurodegenerative diseases. We report that α-syn, from
yeast to neurons, leads to sustained highly elevated levels of cy-
toplasmic Ca2+, thereby activating a CaM-CN cascade that engages
substrates that result in toxicity. Surprisingly, complete inhibition
of CN also results in toxicity. Limiting the availability of CaM shifts
CN’s spectrum of substrates toward protective pathways. Modu-
lating CN or CN’s substrates with highly selective genetic and phar-
macological tools (FK506) does the same. FK506 crosses the blood
brain barrier, is well tolerated in humans, and is active in neurons
and glia. Thus, a tunable response to CN, which has been conserved
for a billion years, can be targeted to rebalance the phosphatase’s
activities from toxic toward beneficial substrates. These findings
have immediate therapeutic implications for synucleinopathies.
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Cells must tightly regulate Ca
2+ homeostasis to avoid patho-
logical perturbations and cell death (1). For example, a pro-
found disruption of Ca2+ homeostasis is seen in Parkinson
disease (PD), the second most common neurodegenerative dis-
order. Mutations or aberrant expression of α-synuclein (α-syn),
a major protein involved in the pathogenesis of PD, can induce
Ca2+ overload and cell death (2–5). Additional clinical and ex-
perimental observations highlight the importance of Ca2+ ho-
meostasis in the pathogenesis of PD. Midbrain dopaminergic
(DA) neurons that overexpress Ca2+-binding proteins, which
buffer intracellular Ca2+, are characteristically spared from de-
generation (6). Patients with hypertension who are treated with
the L-type Ca2+ channel blocker, isradipine, have a lower in-
cidence of PD (7). Moreover, isradipine protects DA neurons
incubated with α-syn fibrils and is protective in animal models of
toxin-induced PD (8–10).
From yeast to mammals, calcineurin is largely responsible for
transducing the signals generated by changes in Ca2+ levels (11).
Calcineurin (CN) is a calmodulin (CaM)-dependent serine/
threonine phosphatase composed of a catalytic subunit (calci-
neurin A, CNA) and an activating regulatory subunit (calci-
neurin B, CNB). As intracellular Ca2+ levels rise, Ca2+ binds to
CNB and CaM, another key calcium signaling protein. Together,
Ca2+-bound CNB and CaM bind CNA, inducing a conforma-
tional change that fully activates the phosphatase (11). Signaling
through CN plays critical roles in processes ranging from stress
response survival in yeast (12) to mammalian development (13).
Despite the compelling link between Ca2+ homeostasis and
PD, we know little about the signaling pathways driven by sus-
tained Ca2+ elevations and how they might lead to cell death
(4, 5). Yeast provide a powerful model system for such inves-
tigations, given their genetic tractability and the remarkable
conservation of Ca2+-signaling pathways from yeast to humans
(14, 15). Moreover, the expression of human α-syn in yeast leads
to cellular pathologies directly relevant to neurons and PD, in-
cluding nitrosative stress (16, 17), defects in vesicle trafficking
(18–20), and faulty mitochondrial function (21, 22).
Results
Intracellular Ca2+ Is Highly Dependent on α-Syn Dosage. The toxicity
of α-syn is extremely dosage sensitive (20, 23). We first asked if the
deregulation of Ca2+ in yeast shows the same extreme sensitivity
to α-syn dosage as does toxicity. We monitored relative cytosolic
Ca2+ levels in strains expressing different levels of α-syn using the
genetically encoded Ca2+ sensor, aequorin. Four yeast strains were
transformed with a plasmid expressing aequorin (Fig. 1 and Fig.
S1A): control cells (expressing yellow fluorescent protein, YFP),
NoTox (expressing α-syn at low, nontoxic levels), IntTox (ex-
pressing α-syn at intermediate, moderately toxic levels), and
HiTox (expressing α-syn at a higher, severely toxic level).
In response to α-syn induction, the NoTox strain exhibited a
reproducible twofold elevation in cytosolic Ca2+. However, this
was transient and Ca2+ levels rapidly returned to normal. The
IntTox strain exhibited a twofold elevation in cytosolic Ca2+
that was stable for 24 h. The HiTox strain, however, reached
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an ∼4-fold elevation in cytosolic Ca2+ at 4 h and cytosolic Ca2+
continued to climb to an almost 65-fold increase by 8 h (Fig. 1A).
The rise in Ca2+ derived from intracellular stores because it
was sensitive to low concentrations of the intracellular calcium
chelator 1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic
acid tetrakis-acetoxymethyl ester, but not to EGTA in the ex-
tracellular medium (Fig. S1B). Importantly, the extreme ele-
vation in intracellular Ca2+ preceded the major onset of cell
death in the HiTox strain (Fig. S1C). Thus, the release of Ca2+
from intracellular stores exhibits strong dependence on the
dosage of α-syn and sustained high levels of Ca2+ are sub-
sequently associated with extensive cell death.
The Rise in Intracellular Ca2+ Is Accompanied by a Decrease in Free
Calmodulin. The delay between Ca2+ elevation and cell death in
the HiTox strain suggested that high Ca2+ levels might initiate
a cascade of events that are ultimately toxic. Calmodulin (CaM
in mammalian cells and Cmd1p in yeast) is a ubiquitous node
through which Ca2+ activates numerous downstream targets. To
determine if CaM plays a direct role in α-syn toxicity, we first
expressed a genetically encoded sensor for free CaM (Fig. S2 A
and B). This genetically encoded sensor for free CaM (BSCaMIQ)
contains a CaM-binding site flanked by CFP and YFP (24, 25). At
low Ca2+ levels, CaM is largely unbound and is therefore able to
bind BSCaMIQ. As cytosolic Ca
2+ rises, CaM engages its targets
and binding to BSCaMIQ decreases, resulting in a real-time
change in fluorescence resonance energy transfer (FRET) be-
tween CFP and YFP. Given that CaM expression is not af-
fected by α-syn in yeast (22), changes in FRET signals from
BSCaMIQ provide a quantitative measure of changes in free
CaM in our strains.
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Fig. 1. BSCaMIQ, a sensor and a sink for calmodulin, rescues toxicity induced by α-syn by decreasing the total levels of free Ca2+–CaM. (A) Strains of control
(no α-syn), NoTox (low copy number of α-syn), IntTox (intermediate copy number of α-syn), and HiTox (high copy number of α-syn) were transformed with
aequorin, a genetically encoded Ca2+ indicator. Cytosolic Ca2+ was measured by aequorin luminescence over time after α-syn induction. Cytosolic Ca2+ levels
are expressed as fold induction relative to control. (B) Cmd1pfree levels assayed by FRET 0, 4, and 8 h after α-syn induction in the presence of BSCaMIQ in
control (blue), HiTox strain (red), and HiTox strain transfected with cmd1 (red dashed line). Cmd1pfree = Kd [(Rmax − FRET/CFP)/FRET/CFP − Rmin] (see Supporting
Information). (C) Yeast strains were spotted onto plates containing uninducing media [synthetic defined (SD) −Ura; GPD-BSCaMIQ selective; Lower] and
replica platted in threefold serial dilutions onto α-syn–inducing plates containing selective media and (SGal −Ura) (Upper). YFP is used as control plasmid. (D)
Yeast strains were spotted onto plates containing uninducing media (SD −Ura, Leu; BSCaMIQ and cmd1 selective; Lower) and replica platted in threefold serial
dilutions onto α-syn–inducing plates containing selective media and SGal −Ura, Leu (Upper). YFP and empty vector (vec) were used as control plasmids,
cmd1 = yeast calmodulin and cmd1X = D94A, E105V; unable to bind calcium at the third EF hand. (E) BSCaMIQ (green), neuronal (red MAP2 positive), and
nuclear (blue, Hoechst) stainings from representative pictures of rat primary neuronal cultures coinfected with either control lentivirus LacZ, LacZ and
α-SynA53T, LacZ and α-SynA53T and BSCaMIQ, or LacZ and BSCaMIQ. (F) Percentages of neurons (MAP2 positive) relative to control (LacZ infected) in the
conditions described in B. *P < 0.05, one-way ANOVA, Dunnett’s multiple comparison test.
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In the control strain, where cytosolic Ca2+ remained low (Fig.
1A), free Cmd1p levels remained high and constant (Fig. 1B). In
the HiTox strain, which experienced a sharp rise in cytosolic Ca2+
(Fig. 1A), free Cmd1p levels plummeted (Fig. 1B). To confirm
that the change in FRET with BSCaMIQ was indeed due to a
reduction in free Cmd1p, we overexpressed cmd1. This restored
normal FRET levels in HiTox cells (Fig. 1B).
Sequestering Free Calmodulin Ameliorates α-Syn Toxicity in Yeast.
The decrease in free CaM caused by α-syn suggests CaM is en-
gaging downstream targets. If this contributes to cell death, the
binding of CaM by BSCaMIQ should compete with those targets
and reduce toxicity. That is, BSCaMIQ should act not only as
a sensor but as a sink for CaM (25) (Fig. S2C). To test this,
control and HiTox strains expressing BSCaMIQ (or a YFP con-
trol) were assayed for growth (Fig. 1C). Indeed, expression of
BSCaMIQ conferred strong protection to the HiTox strain.
Protection by BSCaMIQ was not due to a trivial effect on α-syn
expression (Fig. S2B). Nor was it due to a general response to
proteotoxic stress because cells expressing proteins associated
with other neurodegenerative diseases, polyglutamine expanded
huntingtin fragment (Htt) and TDP43, at similarly toxic levels
were not rescued by BSCaMIQ (Fig. S2 D and E).
Expression of BSCaMIQ did not significantly affect Ca
2+ levels
(Fig. S2F), suggesting that its protection against cell death was
primarily due to the sequestration of Ca2+–CaM. Indeed, the
overexpression of wild-type cmd1 restored toxicity, whereas over-
expression of a cmd1mutant with impaired Ca2+ binding (26) did
not (Fig. 1D and Fig. S2G).
Finally, we tested a completely different CaM sink, the IQ do-
main frommyosin cardiac light chain (CYIQ). This alternative CaM
binder also strongly rescued cells from α-syn toxicity (Fig. S2H).
These findings establish that signaling through Ca2+–CaM-dependent
pathways plays an important role in α-syn toxicity in yeast.
Sequestering Free Calmodulin Ameliorates α-Syn Toxicity in Neurons.
Next, we asked if Ca2+–CaM was relevant to neuronal α-syn tox-
icity. We used primary cells derived from rat embryonic cerebral
cortices as a model because they are relatively homogenous (more
than 80% neurons) and more readily obtained than dopaminergic
neurons. Importantly, cortical neurons are strongly affected in
patients with PD (27).
Rat embryonic cortical neurons were transduced with a lenti-
virus that expresses α-syn A53T, a mutation causing an autoso-
mal-dominant form of PD (28) (about 50% infected; Fig. S3A).
To test the effect of α-syn on Ca2+ homeostasis in these neurons,
we used the Ca2+-sensitive dye Fluo-4. Infected neurons were vi-
sualized with either mKate (control) or an mKate-α-syn fusion
regulated by the synapsin promoter. Cells expressing mKate-α-syn
had increased basal Ca2+ and responded less strongly to KCl-
induced depolarization than cells expressing mKate alone (Fig. S3
B and C). Thus, as previously shown in other primary neuronal
models (2–4), overexpression of α-syn perturbs Ca2+ homeostasis.
To determine if CaM plays a role in the toxicity of α-syn in
neurons, we coinfected A53T-expressing neurons with another
lentivirus encoding BSCaMIQ or a control protein, LacZ. Dif-
ferences in viability were assessed by cellular ATP content as
well as by counting the number of cells positive for microtubule-
associated protein 2 (MAP2), a neuron-specific marker. BSCaMIQ
provided a highly significant, dosage-dependent rescue of α-syn
toxicity (Fig. 1 E and F and Fig. S3D).
Calcineurin Activation by Calmodulin Has both Protective and Toxic
Roles. A central player in transducing Ca2+–CaM’s signals is the
highly conserved phosphatase CN (14). To investigate CN’s role
in α-syn toxicity, we returned to yeast. CN function can be
eliminated by deleting the regulatory subunit cnb1 alone or by
the combined deletion of the catalytic subunits cna1 and cna2.
As expected (29), neither manipulation affected the growth of
the control strain (Fig. 2A and Fig. S4A). In the HiTox cells,
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Fig. 2. Calcineurin activation is central to α-syn toxicity in yeast. (A) Control and HiTox strains lacking calcineurin (cnb1Δ) were spotted onto plates containing
uninducing media (SD −His,Trp–α-syn selective, Lower) and replica plated in threefold serial dilutions on α-syn–inducing plates containing selective media SGal
(Upper). (B) Control and HiTox yeast strains were spotted onto plates containing uninducing media (SD −Ura, Leu; cna1- and cnb1 selective; Lower) and replica
plated in threefold serial dilutions onto α-syn–inducing plates containing selective media and SGal (Upper). (C) Same assay as in B except control and HiTox
strains was plated onto plates containing uninducing media (SD −Leu; rcn1-, or rcn2 selective, respectively). (D) Growth (described as percentage over control)
of HiTox cells grown for 48 h over a range of FK506 concentrations. See also Fig. S4D.
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deleting CN eliminated BSCaMIQ protection (Fig. S4B). Be-
cause BSCaMIQ acts by titrating CaM, and CaM has many tar-
gets, this result suggests that CaM’s main effects in response to
α-syn toxicity are mediated through the calcineurin pathway.
Surprisingly, however, both deletion and overexpression of CN
increased toxicity in the HiTox strain (Fig. 2 A and B). One ex-
planation for these apparently contradictory results is that an in-
termediate level of CN activation is protective against α-syn,
whereas either too much or too little is detrimental.
As a genetic test of this hypothesis, we used Rcn proteins as
negative regulators of CN activity. Rcn1p has a higher affinity for CN
than Rcn2p (30). Whereas neither protein affected the control strain,
overexpressing rcn2 (but not rcn1) rescued α-syn toxicity (Fig. 2C).
As a pharmacological approach, we used FK506. Importantly,
FK506 provides a means to continuously vary CN inhibition over
a very broad range. FK506 inhibits CN by precisely the same
mechanism in yeast and in mammals (29, 31) although higher
concentrations of this drug are required in yeast than in mam-
malian cells (Materials and Methods). Consistent with our hy-
pothesis, in the HiTox strain intermediate concentrations of
FK506 protected against α-syn toxicity, whereas higher concen-
trations eliminated this protection (Fig. 2D).
MAP2 stainingA
0 .01 .1 1 10 0 .01 .1 1 10
control SynA53T
A
TP
c
o
n
te
nt
(%
C
on
tro
l)
*
FK506 [uM]
B
ce
ll
su
rv
iv
al
(%
Co
nt
ro
l)
control -SynA53T
0 0 0.1 10
FK506 [uM]
** *
TH -Syn Merge
C
control
-Syn +
vector RNAi
-Syn +
CN RNAi
W
or
m
s
w
ith
W
T
D
A
n
eu
ro
n
s
(%
)
20
40
30
10
0
Syn
vector CN
RNAi RNAi
D
0
50
30
20
10
40
1 2
rcn-1 rcn-1
W
or
m
s
w
ith
W
T
D
A
n
eu
ro
n
s
(%
)
Syn
E
LacZ/vehicle
A53T/
1uM FK506
A53T/
10uM FK506A53T/vehicle
A53T/
0.1uM FK506
100
75
50
25
0
100
80
60
40
0
20
Fig. 3. Partial calcineurin activity is necessary to protect against α-syn toxicity ex vivo and in vivo. (A, Upper) MAP2 staining from representative pictures of
rat primary neuronal cultures coinfected with a lentivirus carrying LacZ as control and/or α-synA53T treated with various doses of FK506 for 14 d. (Lower) Rat
cortical neurons infected with α-synA53T and/or LacZ as control treated with vehicle and/or increasing concentrations of FK506 for 14 d and assayed for
viability for ATP content. *P < 0.05, one-way ANOVA, Dunnett’s multiple comparison test. Each data point was normalized against control LacZ at the same
FK506 dose. (B, Upper) Dopaminergic neurons from mice infected with α-synA53T and/or mKate as control treated with vehicle and/or distinct concentrations
of FK506. Cell survival was measured by counting TH positive neurons after 14 d of α-synA53T infection and drug treatment. *P < 0.05, one-way ANOVA,
Dunnett’s multiple comparison test. (Lower) Representative pictures of infection efficiency of mKate α-syn in TH positive neurons. (C) Representative images
of C. elegans dopaminergic neurons in worms expressing GFP alone (Left, all six anterior neurons are intact) and in α-syn–expressing worms treated with RNAi
control (only four anterior DA neurons remain) or with RNAi for calcineurin (CN) (Right). Arrowheads show intact dopaminergic neuron cell bodies and arrows
represent areas where dopaminergic neurons are absent. (D) The population of worms with WT (wild type) numbers of neurons remaining after treatment
with RNAi for calcineurin (CN) or empty vector RNAi (control) in α-syn–expressing worms. For each experiment, three independent experiments were per-
formed, with 30 worms per trial. *P < 0.05 (Student t test). See also Fig. S5C. (E) Same assay as in D except with worms overexpressing rcn-1. Bars 1 and 2
represent independent transgenic lines. *P < 0.005, **P < 0.0005 (Student t test). See also Fig. S5B.
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Importantly, rescue by intermediate concentrations of FK506
in the HiTox strain was not due to a trivial effect on α-syn ex-
pression (Fig. S4C). Furthermore, the lack of rescue at high
concentrations was not due to off-target toxicity, because FK506
had no effect on control cells even at the highest concentrations
used (Fig. S4D). Moreover, FK506 effects were specific to the
HiTox strain where CN activity is high: the compound had no
effect on the less toxic IntTox strain, which has much lower levels
of cytosolic Ca2+ (Fig. 1A and Fig. S4E). We further confirmed
FK506 effects on CN activity using BSCaMIQ, which sequesters
CaM and reduces CN activation. The effects of FK506 should be
greatly reduced in HiTox cells carrying BSCaMIQ, and indeed
they were (Fig. S4F).
Thus, both genetic and pharmacologic experiments in yeast con-
firm that an intermediate level of CN inhibition balances the pro-
tective versus toxic effects of Ca2+–CaM/CN in response to α-syn.
Decreasing Calcineurin Activity Protects Against α-Syn Toxicity in
Neuronal Models. Next, we asked if modulating CN activities
could balance toxic versus protective responses to α-syn in primary
rat cortical neurons. At all concentrations, FK506 had only a mi-
nor effect on the viability of neurons expressing the control pro-
tein LacZ (Fig. 3A). Intermediate concentrations of FK506
rescued neurons from the toxic effect of α-syn expression. (Note,
in keeping with the fact that neurons have many more mechanisms
for buffering calcium than yeast cells do, the concentration range
for rescue was much broader in neurons than in yeast, spanning
a 100-fold range.) Higher concentrations of FK506 were not
protective and, in fact, increased toxicity (Fig. 3A).
We next asked if FK506 was protective in dopaminergic neu-
rons, the cell type most classically implicated in Parkinson disease.
We used primary cultures containing 30–40% dopaminergic neu-
rons assessed by tyrosine hydroxylase (TH) positivity. To allow
unambiguous identification, we infected neurons with an adeno-
associated virus encoding human α-synA53T tagged with mKate or
with mKate alone (Fig. S5A). Fourteen days after infection, ∼30%
of the dopaminergic neurons expressing α-syn had died. In-
termediate levels of FK506 rescued cells from α-syn toxicity,
whereas the protective effects of the drug disappeared at higher
doses (Fig. 3B).
To begin moving into multicellular organisms, we took advan-
tage of a previously established nematode model of α-syn toxicity
(32). In these worms, GFP and α-syn are both under the tran-
scriptional control of the dopaminergic neuron-specific dat-1
promoter. Wild-type (WT) worms invariably have six dopami-
nergic neurons. As previously reported (18), expression of α-syn
caused an age- and dose-dependent degeneration of dopaminergic
neurons (Fig. 3C). We down-regulated CN activity in this model
using two methods: direct knockdown of CN with RNAi and
overexpression of its negative regulator, rcn-1.
To allow RNAi targeting of CN in DA neurons, we expressed
the dsRNA transporter SID-1 in these cells using the dat-1
promoter (33). Knockdown of the catalytic subunit of CN, tax-6,
had no effect on the dopaminergic neurons of control worms
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(Fig. S5C). However, in α-syn–expressing worms, reducing the
expression of CN by knockdown protected against toxicity (Fig. 3
C and D).
Nematodes have only one known negative regulator of CN, rcn-1
(34). Several independent transgenic lines were established with
different levels of rcn-1 expression. In two transgenic lines, we
found that moderate rcn-1 expression was nontoxic (Fig. S5B) and
also protected dopaminergic neurons against α-syn toxicity (Fig.
3E). Thus, establishing a biological mechanism conserved from
single cells (yeast and primary mammalian neurons) to whole
worms, chemical and genetic approaches, demonstrate that mod-
erating CN activity is protective against α-syn toxicity.
Protective and Toxic Downstream Substrates of Calcineurin. Our
finding that an intermediate level of CN activity is protective
against α-syn suggests that some CN downstream targets provide
protection, whereas others enhance toxicity. To investigate, we
returned to yeast, focusing on three of CN’s best characterized
substrates: Hph1p, Slm2p, and Crz1p. Remarkably, the processes
regulated by all of these proteins are disturbed by α-syn in yeast
and in neurons. Hph1p facilitates the posttranslational trans-
location of proteins, especially those involved in vacuolar ion ho-
meostasis and vesicular trafficking (35). Slm2p acts via the target of
rapamycin complex 2 (TORC2) to support cytoskeletal organiza-
tion and lipid homeostasis (20, 36–38). Crz1p is a transcription
factor activated by calcineurin in response to various stresses (39).
Importantly, overexpression of these genes under nonstress con-
ditions had no effect on control cells (Fig. S6A).
Overexpressing hph1 or slm2 rescued α-syn toxicity in the
HiTox strain (Fig. 4A). Overexpressing crz1, however, slightly
enhanced toxicity. To better characterize this enhancement of
toxicity, we overexpressed crz1 in the HiTox strain in the pres-
ence of BSCaMIQ. Overexpression of crz1 completely abrogated
the protective effects of BSCaMIQ, confirming the role of crz1 in
enhancing α-syn toxicity and validating the effect of BSCaMIQ
on the CN pathway (Fig. S6B). Thus, Hph1p and Slm2p drive
protective pathways in response to α-syn, whereas Crz1p drives
detrimental ones.
We focused further on the protective substrate Slm2p and the
toxic substrate Crz1p, because Slm2p and Crz1p pathways are
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conserved from yeast to humans. Because CN is a phosphatase,
we began by investigating the effect of α-syn on the phosphory-
lation status of Slm2p and Crz1p using selected reaction moni-
toring (SRM)-based mass spectrometry (MS) (40). This technique
avoids the use of artificial protein tags, which can interfere with
protein function, and more importantly, gives information about
the nature of the phosphorylation sites in a highly specific and
quantitative manner.
α-Syn expression increased Slm2p phosphorylation. Protective
doses of FK506 further increased phosphorylation, whereas toxic
doses blunted it (Fig. 4B). Although the role(s) of phosphorylation
in regulating Slm2p activity is not clear, this result is consistant
with an interaction between CN and Slm2p driving a protective
response against α-syn toxicity. To test this, point mutations in
Slm2p that selectively abrogate its interaction with CN (41)
eliminated protection against α-syn toxicity, although having no
effect on control strains (Fig. 4C and Fig. S6C).
Slm2p acts upon the TORC2 signaling pathway (38). To see
whether this pathway is also affected by α-syn, we assayed the
expression of two yeast genes that are classically up-regulated when
TORC2 is inhibited (42). ylr194c and dia1 were both up-regulated
in response to α-syn expression, indicating that α-syn does indeed
inhibit the TORC2 pathway (Fig. 4D). As predicted from their
effects on CN, overexpression of slm2 or moderate concentrations
of FK506 both decreased expression of ylr194c and dia1, indicating
a restoration of TORC2 function (Fig. 4D).
Activation of the transcription factor Crz1p is normally pro-
tective for yeast cells under stress (39). However, our results
suggest that Crz1p drives a toxic response to α-syn. Phosphory-
lation of Crz1p inhibits its transcriptional activity. Using SRM to
monitor Crz1p phosphorylation, we found that it was reduced in
response to α-syn, whereas protective and toxic doses of FK506
increased it (Fig. 4E). A mutant of Crz1p with increased affinity
for CN (43) had no effect on control cells but increased toxicity
in cells expressing α-syn (Fig. 4F and Fig. S6D). This high-affinity
allele of crz1 also reduced the protective effect of BSCaMIQ,
confirming that CaM’s role in α-syn toxicity is mediated through
the CN pathway (Fig. S6E). Further, deleting crz1 strongly res-
cued growth in HiTox cells (Fig. 4F and Fig. S6D).
If Crz1 activation is indeed driving a toxic transcriptional
response to α-syn, Crz1p’s transcriptional activity should be
up-regulated in the HiTox strain. Moreover, if this activity is
connected to the Ca2+–CaM/CN pathway cascade, it should be
down-regulated by BSCaMIQ, by protective concentrations of
FK506 or by deletion of CN. Using a β-galactosidase reporter for
Crz1p transcriptional activity (44), each of these predictions was
fulfilled (Fig. 4G). Thus, α-syn activates a toxic Crz1p-regulated
response to Ca2+ in yeast. Moderate inhibition of CN activity
prevents activation of this toxic pathway while still allowing
protective responses mediated through substrates such as Slm2p
to remain intact.
Downstream Consequences of Calcineurin Activation by α-Syn in
Mice. To determine whether the effects of α-syn demonstrated
in yeast are conserved in the central nervous system of mammals,
we turned to an α-syn transgenic mouse model where α-syn is
overexpressed in various regions of the brain, including areas
affected in PD such as the olfactory bulb and cortex (45, 46). As
they age, these mice display phenotypes reminiscent of PD, in-
cluding neuroinflammation (increased numbers of astrocytes and
microglia), as well as neuronal pathology. Calcineurin is highly
expressed in both glia and neurons and, hence, could potentially
contribute to protective or toxic responses in both.
First, we probed the status of the TORC2 pathway (activation
was protective in yeast). In the brains of 12-mo-old mice, we
monitored protein kinase C alpha (PKCα) phosphorylation at
serine 657, a canonical downstream substrate of TORC2. PKCα
phosphorylation was reduced in brain extracts from α-syn–over-
expressing mice compared with controls (Fig. 5A). Thus, the
inhibition of PKCα correlates with inhibition of the TORC2
pathway in mammalian brain in response to α-syn.
Although no direct homolog of crz1 exists in mammalian cells,
nuclear factor of activated T cells (NFAT) is broadly accepted as
its functional analog (41). Similar to Crz1p, calcineurin dephos-
phorylates various isoforms of NFAT, leading to their nuclear
translocation. We monitored two isoforms, NFATc4 and NFATc3,
which we found to be prominent in neurons and glia, respectively.
In agreement with our yeast results, the neurons from the olfactory
bulbs of the α-syn transgenic mice displayed increased nuclear
neuronal localization of NFATc4, consistent with its activation
(Fig. 5B). NFATc3 staining intensity and nuclear localization was
increased in glia (Fig. 5B), indicating that it, too, was activated.
Thus, a calcineurin-mediated response to α-syn was also conserved
in the mammalian brain, in both neurons and glia.
NFAT Is Activated in Human Synucleinopathies. Finally, we examined
NFAT activation in fixed postmortem tissue from humans di-
agnosed with PD or with a more aggressive synucleinopathy,
dementia with Lewy bodies (DLB). We could not detect
NFATc3; however, staining of NFATc4 was highly reproducible
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and specific, as it was competed with a peptide that was used to
raise the antibody (Fig. S7). Four of the five brains we analyzed
from nondiseased controls exhibited cytoplasmic but no nuclear
staining for NFATc4. In contrast, NFATc4 immunoreactivity
was localized to nuclei in most of the eight cases of PD and DLB
consistent with its activation (Fig. 6).
The nuclear staining for NFATc4 in the diseased brains was
evident across several different brain regions including the sub-
stantia nigra pars compacta (SNc), hippocampus, and frontal
cortex, among others. In the frontal and cingulate cortices, nuclear
NFATc4 staining was most prominent in the pyramidal neurons in
layers 5 and 6. In DLB, these cortical layers bear the greatest
burden of α-syn pathology (27). In the hippocampus, which is also
critically involved in PD pathology (47), areas CA3 and CA4
stained more strongly than CA1 or CA2 or the subiculum. These
results support an association between NFATc4 nuclear localiza-
tion/activation and α-syn toxicity in human disease.
Discussion
We demonstrate that increasing levels of α-syn expression pro-
portionally increase cytosolic Ca2+ concentrations, paralleling
the extremely strong dosage dependence of α-syn toxicity pre-
viously described in our yeast models (18, 20) and in humans (23,
48). Sustained high cytosolic Ca2+ levels drive a Ca2+–CaM–
calcineurin cascade that activates a toxic program regulated by
the transcription factor Crz1p in yeast and NFAT in mammalian
cells. However, calcineurin activation also triggers protective
responses against α-syn involving TORC2. The balance between
these responses and presumably other unidentified calcineurin
substrates is critical in determining the ultimate outcome of ac-
tivating the Ca2+–CaM–calcineurin pathway in response to α-syn
(Fig. S8). Importantly, this multifaceted calcineurin-mediated
response to α-syn, although first uncovered in yeast, is conserved
in nematodes as well as mammalian neurons, glia, and brains, as,
indeed, are the protective effects of moderate concentrations
of FK506.
How does α-syn lead to increased cytosolic Ca2+? Our data
clearly indicate that it is released from intracellular stores. Given
the lipid-binding properties of α-syn, the protein might perturb
Ca2+ homeostasis directly (through damage to the membrane or
membrane channels) or indirectly [as a consequence of the pro-
found block in endoplasmic reticulum (ER) to Golgi trafficking].
How might increased cytosolic Ca2+ determine calcineurin’s
switch between protective and toxic substrates in a concentration-
dependent manner? Differences in the sequence and accessibility
of substrate docking sites, expression levels, and the number of
dephosphorylations required to alter a substrate’s activity are all
likely involved. These, in turn, will interface with differences in the
degree of calcineurin activation, determined by cellular levels of
CaM and Ca2+ in different compartments within the cell. Given
the complexity of this problem, many strategies, including the use
of genetically tractable organisms such as yeast, will be required to
achieve a full understanding.
Because inhibition of calcineurin activity is routinely exploited
clinically through the use of FK506 (tacrolimus) as an immu-
nosuppressant, we now suggest that the repurposing of FK506,
a compound that readily traverses the blood brain barrier merits
investigation in the management of PD. Because it persists in the
central nervous system long after systemic effects have resolved
(49), intermittent dosing with this already FDA-approved drug
could avoid systemic immunosuppression, while still providing
a readily implemented, disease-modifying treatment strategy
that targets a fundamental mechanism in the pathogenesis of
α-synucleinopathies.
Indeed, FK506 was previously shown to have neuroprotective
properties in mammalian PD models (50–53). Because FK506
impairs calcineurin function by locking it into a complex with
FKBP12, FK506’s neuroprotective effects were thought to be me-
diated through FKBP12. Compounds that target FKBP12, without
affecting calcineurin function, prevented neurodegeneration in
specific animal models (54, 55) but failed to show reversal of
PD motor symptoms in humans (56). Although we have yet to
address any potential contributions of FKBP12 to the pro-
tective effects of FK506 that we have seen, our findings clearly
establish the importance of reducing calcineurin activity to
achieve neuroprotection.
Finally, our findings help explain why in PD, DA neurons in
the SNc are particularly sensitive to α-syn–related dysfunction.
Adult neurons in the SNc rely on voltage-dependent Ca2+
channels. These channels are regulated by CaM binding (57, 58)
and drive autonomous pacemaking, which leads to relatively
sustained elevations in cytosolic Ca2+ (9, 59). Intriguingly, CaM can
be cross-linked to α-syn (60, 61), suggesting that α-syn could be
locally sequestering CaM to further increase cytosolic Ca2+ flux
through these channels. Moreover, SNc neurons have higher
cytosolic dopamine levels than the less susceptible ventral teg-
mentum DA neurons (62). This neurotransmitter renders SNc
neurons more susceptible to cell death and has also been linked to
increased intracellular Ca2+ levels (62). The enhanced sensitivity
of the SNc DA neurons to Ca2+ stress would exacerbate the
defects in vesicle trafficking (18, 63, 64), mitochondrial dysfunc-
tion (21, 22), nitrosative stress (16, 17), and metal ion homeostasis
(65) caused by α-syn. The combination is poised to create the
“perfect storm” that devastates the SNc of patients with PD.
Materials and Methods
Primary Cells and Strains. Yeast strains containing α-syn were generated and
induced as previously described (18). Rat cortical and mouse dopaminergic
neurons were infected with a lentivirus carrying α-syn as described in SI
Materials and Methods. In vivo models for α-syn in Caenorhabditis elegans and
mice where generated as described (32, 46). Human samples from PD and DLB
patients were obtained through the Massachusetts Alzheimer Disease Re-
search Center as described in SI Materials and Methods.
Imaging Techniques. Ca2+ imaging was performed using aequorin (in yeast)
and Fluo-4 (in neurons). CaM measurements were performed using FRET.
MAP2 and TH staining in neurons were performed by immunofluorescence.
NFAT staining in mice and human samples were performed by immunohis-
tochemistry. Detailed description of all imaging techniques can be found in SI
Materials and Methods.
Viability Assays. For neurons we used ATP and MAP2 positive staining,
whereas for yeast cells, spotting assays, growth curves using OD600, and
propidium idodine incorporation by cell cytometry were performed as via-
bility assays. Detailed description of all viability techniques can be found in SI
Materials and Methods.
Biochemistry Assays. To monitor phosphorylation of substrates selected re-
action monitoring assays was performed. To monitor Crz1p activity in yeast we
used the Crz1-dependent reporter element-luciferase reporter (44). Detailed
description of these techniques can be found in SI Materials and Methods.
Molecular Biology. RCN-1 overexpression and quantitation C. elegans was
performed as described (34). RNA interference (RNAi) in C. elegans was per-
formed as described (33). CaM mutants were performed by QuikChange XL
site-directed mutagenesis as described in SI Materials and Methods.
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